4
ESMO-MCBS v1.1
Scorecard version: 1
Indication details
- Tumour Type
- Thoracic Malignancies
- Tumour Sub-type
- Non-small-cell Lung Cancer
- Tumour Sub-Group
- EGFR+
- Tumour stage
- Advanced
- Control Arm
- Platinum/pemetrexed
- Treatment Setting
- 2nd line for EGFR mutated NSCLC after TKI with new T790M mutation
- Trial Name
- AURA3
Primary Outcome(s)
- Primary Outcome(s)
- PFS (crossover allowed)
- Form(s)
- Form 2b
Outcome Data
- PFS Control
- 4.4 months
- PFS Gain
- 5.7 months
- PFS HR
- 0.30 (0.23-0.41)
- QoL Comment
- Improved patient reported outcomes
- Toxicity Comment
- Reduced toxicity
Final Score (after adjustments)
- Preliminary non-curative score
- 3
- Toxicity adjustment
- 1+
- Final non-curative Score
- 4
- Last update
- 30.04.2020
DFS, disease-free survival; DoR, duration of response; EFS, event-free survival; HR, hazard ratio; iDFS, invasive disease-free survival; ITT, intention to treat; ORR, overall response rate; OS, overall survival; pCR, pathologic complete response/remission; PFS, progression-free survival; PE, point estimate; QoL, quality of life; RFS, relapse-free survival; RR, response rate; SD, stable disease; SSA, somatostatin analogue; SSTR, somatostatin receptor; TKI, tyrosine kinase inhibitor, TTP, time to progression